Qu et al. 82 demonstrated that MCC950, which is known as an NLRP3 inhibitor, significantly alleviates bile duct ligation-induced liver fibrosis by reducing IL-18 and IL-1β expression, and suppressing neutrophil infiltration and hepatic cell death. Here, IL1B is linked to Hepatic fibrosis.